FIGURE 5.

miR‐193a‐3p potentiates the efficacy of dabrafenib and trametinib (DAB/TRA) and DAB/TRA plus Cmab in BRAF‐mutated colorectal cancer (CRC) cells. A, miR‐193a‐3p overexpression enhanced the inhibition of cell proliferation after treatment with DAB alone and DAB/TRA combination for 48 h in RKO cells. B, Inhibition of cell growth after treatment with DAB/TRA and DAB/TRA plus Cmab for 60 h was potentiated by overexpression of miR‐193a‐3p. C, D, Western blots show that miR‐193a‐3p overexpression enhanced the efficacy of DAB/TRA and DAB/TRA plus Cmab for 36 h and suppressed MAPK reactivation in RKO cells. Numbers below each band represent the expression levels of each protein relative to that of tubulin or β‐actin, as determined by densitometry. Relative protein expression was calculated by normalization to negative control of miRNA mimic (NC‐mimic) with DMSO treatment. E, Potential model for miR‐193a‐3p regulation of efficacy of DAB/TRA in BRAF‐mutated CRC. Overexpression of miR‐193a‐3p in addition to DAB/TRA treatment inhibited reactivation of p‐CRAF and intensified reduction of Mcl1, p‐AKT, and MYC. *P < .05; **P < .01